Skip to main content
. 2021 Oct 11;22(20):10954. doi: 10.3390/ijms222010954

Figure 8.

Figure 8

The combination effect of an AR antagonist with EGFR/AKT inhibitor in U87MG subclones. U87MG WT, U87MG EGFR, and U87MG EGFRvIII cells were treated for 72 h with 1.25 μM afatinib (Afa) (striped columns) or 20 μM enzalutamide (Enz; white columns) alone or in combination (black columns); 2.5 μM MK2206 (striped columns) or 20 μM enzalutamide (Enz; white columns) alone or in combination (black columns). Cell density is expressed as the percentage of cells treated with vehicle (gray columns). The results are the mean ± SD. * p < 0.05 indicates significant results of each treatment compared to vehicle-treated cells (Student’s two-tailed t-test).